The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention

J Leukoc Biol. 2020 May;107(5):731-738. doi: 10.1002/JLB.2MR1119-224R. Epub 2020 Feb 13.

Abstract

CD137 is a potent costimulatory receptor. Several agonistic anti-CD137 antibodies are currently in clinical trials for tumor immunotherapy. Soluble forms of CD137 (sCD137) are generated by differential splicing and antagonize the activities of membrane-bound CD137 (mCD137) and of therapeutic CD137 agonists. sCD137 is found in sera of patients suffering from autoimmune diseases where it is a natural regulator of immune responses, and which has therapeutic potential for immune-mediated diseases. This review summarizes the current knowledge on sCD137, highlights its potential role in immunotherapy against cancer and in autoimmune diseases, and presents important issues to be addressed by future research.

Keywords: CD137; autoimmune; cytokine receptor; soluble.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / therapy
  • Humans
  • Immunotherapy / methods
  • Neoplasms / immunology
  • Neoplasms / therapy
  • Tumor Necrosis Factor Receptor Superfamily, Member 9 / immunology*

Substances

  • Tumor Necrosis Factor Receptor Superfamily, Member 9